过去一年中添加的文章,按日期排序

The Effectiveness and Tolerability of Switching Patients from Sacubitril/Valsartan, ARNI to Perindopril in Heart Failure with Reduced Ejection Fraction: Efficient Trial

P Jariwala, D Gude, PS Reddy… - Indian Journal of …, 2024 - journals.sagepub.com
11 天前 - sacubitril/valsartan in India is mostly attributed to its exorbitant price, despite its
established advantages. ARNI failed to meet the cost-effectivenesssafe and effective in patients

Sacubitril/Valsartan in Patients With Heart Failure and Deterioration in eGFR to< 30 mL/min/1.73 m2

S Chatur, IE Beldhuis, BL Claggett, FR McCausland… - JACC: Heart Failure, 2024 - Elsevier
23 天前 - … the safety and efficacy of continuing sacubitril/valsartan in … sacubitril/valsartan is
guideline recommended in the management of patients with heart failure with reduced ejection

[HTML][HTML] Effect of sacubitril-valsartan on left ventricular remodeling and NT-proBNP in patients with heart failure complicated with hypertension and reduced ejection …

B Xie, Q Gao, Y Wang, J Du, Y He - American Journal of …, 2024 - ncbi.nlm.nih.gov
27 天前 - … Instead, it effectively mitigated heart failure exacerbation and … and safety profile
of sacubitril/valsartan [27,28]. In conclusion, sacubitril/valsartan demonstrates superior efficacy

… Coated Tablets of Sacubitril Valsartan Supramolecular Complex Using Hupu and Lannea Gums A Conceptual Approach In The Treatment of Chronic Heart Failure

R Aleti - shodhganga.inflibnet.ac.in
40 天前 - … Abstract: Sacubitril-valsartan supramolecular complex (SVSC), a first-inclass … as
safe and effective treatment for heart failure with reduced ejection fraction. newline newline …

From Emergency Department to clinic center: management of patients with Heart Failure with Reduced Ejection Fraction

J Mambella, F Foieni, G Sala, P Ghiringhelli… - Working Paper of …, 2024 - pagepress.org
46 天前 - … a better evaluation of the efficacy and safety of different treatment options,… safety
features, our results could be considered in line with the literature data for sacubitril-valsartan (…

[HTML][HTML] Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia: REALIZE-K Design and Baseline Characteristics

MN Kosiborod, D Cherney, K Connelly, AS Desai… - JACC: Heart Failure, 2024 - Elsevier
46 天前 - … in patients with heart failure with reduced ejection fraction (HFrEF) because of its
established benefits including lower rates of heart failure (… clarify the safety and efficacy of SZC …

Effect of Sacubitril/Valsartan on Patients Having Heart Failure With Preserved Left Ventricular Ejection Fraction Undergoing Hemodialysis: A Long-term Observational …

A Mima, H Gotoda, S Lee, R Lee, A Murakami, R Akai… - in vivo, 2024 - iv.iiarjournals.org
66 天前 - … neprilysin inhibitors, is effective in treating heart failure (HF) by … of heart failure
with preserved ejection fraction (… Our results demonstrated the safety of SV in patients with …

Efficacy of early administration of sacubitril/valsartan after coronary artery revascularization in patients with acute myocardial infarction complicated by moderate-to …

H Yin, L Ma, Y Zhou, X Tang, R Li, Y Zhou, J Shi… - Heart and Vessels, 2024 - Springer
71 天前 - ventricular remodeling in patients with heart failure, especially heart failure with
reduced ejection … was to evaluate the efficacy and safety of sacubitril/valsartan in these patients. …

Effects of sacubitril/valsartan across the spectrum of renal impairment in patients with heart failure

S Chatur, BL Neuen, BL Claggett, IE Beldhuis… - Journal of the American …, 2024 - jacc.org
83 天前 - … (This Study Will Evaluate the Efficacy and Safety of … of patients with heart
failure with reduced ejection fraction (HFrEF). Furthermore, the clinical benefits of sacubitril/valsartan

EFFECT OF SACUBITRIL/VALSARTAN ACCORDING TO POLYPHARMACY STATUS IN PARAGON-HF

S Matsumoto, M Yang, L Shen, B Claggett… - Journal of the American …, 2024 - jacc.org
87 天前 - Patients with heart failure and preserved ejection fraction (HFpEF) have a particularly
efficacy and safety of sacubitril/valsartan according to polypharmacy status in patients